tbuckley/cabot-search huggingface dataset:
CD70 Expression on HTLV-1 Infected T Cells of Carriers and ATL Patients and Its Clinical Significance
Authors: Izumi Masamoto, Sawako Horai, Tomohiro Kozako, Makoto Yoshimitsu, Junko Niimoto, Yohann White, Kimiharu Uozumi, Shinsuke Suzuki, Naomichi Arima
Journal: Blood (2010)
Prevention of preeclampsia
Authors: Chad A. Grotegut
Journal: Journal of Clinical Investigation (2016)

Preeclampsia is a common complication of pregnancy that is associated with an increased risk of maternal and neonatal morbidity and mortality. Currently, delivery is the only cure for preeclampsia; therefore, effective prevention and treatment options for this condition are sorely needed. In the current issue of the JCI, Mirzakhani et al. report the findings of the Vitamin D Antenatal Asthma Reduction Trial (VDAART), a well-conducted large, randomized, double-blind, placebo-controlled trial of vitamin D supplementation for the prevention of preeclampsia. Though vitamin D supplementation had no effect on the risk of preeclampsia, reduced maternal serum vitamin D levels did correlate with preeclampsia risk. Mirzakhani and colleagues identified a number of gene pathways that are differentially regulated among women with low serum vitamin D levels who develop preeclampsia. These results indicate that further research on the role of vitamin D in preeclampsia is warranted.
HLA Ligandome Analysis in Primary Polycythemia Vera (PV) Samples Shows No Tumor-Association of Naturally Presented JAK2 Ligands but Reveals a Vast Array of Novel PV-Associated HLA Ligands
Authors: Juliane S. Stickel, Daniel J. Kowalewski, Steffen Koschmieder, Lothar Kanz, Helmut R. Salih, Tim H. Brümmendorf, Hans-Georg Rammensee, Stefan Stevanovic
Journal: Blood (2014)
AB0812 Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Review of 63 Cases
Authors: D. Amri, K. Baccouche, K. Zahra, B. Monia, S. Belghali, N. Elamri, Z. Alaya, H. Zeglaoui, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Multiple myeloma is a malignant disorder in which plasma cells accumulate in the bone marrow and produce an entire immunoglobulin (usually IgG or IgA) or only immunoglobulin light chains (kappa or lambda). Multiple myeloma accounts for approximately 10% of hematologic cancers and 1% of all cancers. In recent years there is huge improvement in treatment of patients with multiple myeloma. The milestone of these improvement is the Autologous hematopoietic stem cell transplantation <h3>Methods</h3> We analyzed results of 63 consecutive patients (16 male and 47 female) of MM who underwent Autologous hematopoietic stem cell transplantation (ASCT). <h3>Results</h3> A review of 63 cases of multiple myeloma seen from 2006 through 2015 revealed that The median age was 59,1 years (range: 38–80) and that 25% of them were male. Inital findings were bone pain in 73,8% of patients, anemia in 14%, renal insufficiency in 11% and hypercalcemia in 34,9%. Proteinuria was noted in 10% and Bence Jones proteinuria was identified in 5,2%. Skeletal roentgenographic abnormalities were seen in 78%. Serum proteinelectrophoresis showed a spike in 83% and hypogammaglobulinemia in 17%. Immunoelectrophoresis of the serum revealed a monoclonal heavy chain in 80% and a monoclonal light chain in the serum, in 5.2% (Bence Jones proteinemia). ASCT was performed in 15 patient (age &lt;65ans); Post ASCT 47,1% of patients achieved complete reponse, 24,2% had very good partial response (VGPR), and 38.7% had partial response (PR). <h3>Conclusions</h3> Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment. <h3>Disclosure of Interest</h3> None declared
Safety of Clofarabine with Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (Vandevol study of the French SFCE Acute Leukemia Committee).
Authors: Brigitte Nelken, Guy Leverger, Claire Galambrun, Genevieve Plat, Claudine Schmitt, Caroline Thomas, Cécile Vérité, Benoit Brethon, Virginie Gandemer, Yves Bertrand, André Baruchel, Pierre Rohrlich
Journal: Blood (2012)
OC-070 Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) with Diarrhoea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups
Authors: B Lacy, W Chey, A Lembo, LS Dove, PS Covington
Journal: Gut (2016)

<h3>Introduction</h3> Eluxadoline (ELX) is a mixed µ- and κ-opioid receptor (OR) agonist and δ-OR antagonist. It is locally active and approved for the treatment of IBS-D. The effectiveness of ELX was evaluated in clinically relevant subgroups from pooled data from Phase 3 clinical trials. <h3>Methods</h3> Two double-blind, placebo (PBO)-controlled, Phase 3 clinical trials (IBS-3001 and IBS-3002) randomised patients meeting Rome III criteria for IBS-D to twice-daily treatment with ELX (75 or 100 mg) or PBO. Patients rated IBS symptoms daily including worst abdominal pain (WAP; 0–10 scale) and stool consistency (Bristol Stool Scale). The primary endpoint was composite response (based on simultaneous daily improvement in WAP and stool consistency with ≥50% of days demonstrating a response) evaluated over Weeks 1–12. Subgroup analyses were conducted on the pooled ITT population with comparisons based on a Cochran–Mantel–Haenszel analysis. Subgroups aincluded those based on gender, histories of gastroesophageal reflux disease (GERD) and depression, and prior cholecystectomy status. The impact of baseline IBS pain severity (&lt;5, 5– &lt;8, and ≥8) was examined with a stratified analysis. <h3>Results</h3> 2423 patients with IBS-D were included. The majority of patients were female (66%) and had baseline WAP scores of 5– &lt;8. Histories of GERD and depression were reported for 31% and 25% of patients, respectively, and 20% of patients had a prior cholecystectomy. In males and females, significantly more patients (p ≤ 0.002) receiving ELX 75 and 100 mg were composite responders than patients receiving PBO (Table). Additionally, significantly greater responder proportions were seen with ELX treatment among patients with histories of GERD (75 and 100 mg) and depression (100 mg), or among patients with a prior cholecystectomy (75 and 100 mg) [Table]. When stratified by baseline WAP, responder proportions were significantly higher for both eluxadoline groups (p &lt; 0.001) vs. placebo. <h3>Conclusion</h3> Overall, treatment with ELX is effective in both male and female patients with IBS-D and multiple relevant subgroup populations based on composite response. <h3>Reference</h3> 1 Previously presented at ACG 2015. Abstract #1760, <i>Am J Gastroenterol</i> 2015;<b>110</b>:S739–S766. doi:10.1038/ajg.2015.275. <h3>Disclosure of Interest</h3> B. Lacy Consultant for: Ironwood, Takeda, Salix, Allergan plc, Covidien, W. Chey Grant/research support from: Ironwood, Nestle, Prometheus, Vibrant, Perrigo, Consultant for: Allergan plc, Ardelyx, Asubio, AstraZeneca, Ironwood, Nestle, Prometheus, Salix/Valeant, Sucampo, Takeda, Conflict with: My GI Health, My Nutrition Health, Digital Monometry, My Total Health, A. Lembo Consultant for: Allergan plc, L. Dove Consultant for: Allergan plc, P. Covington: None Declared
Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity.
Authors: Avichai Shimoni, Izhar Hardan, Noga Shem-Tov, Moshe Yeshurun, Ronit Yerushalmi, Isaac Ben-Bassat, Arnon Nagler
Journal: Blood (2005)
Bortezomib Induced Peripheral Neuropathy Is Related to Altered Level of Brain Derived Neurotrophic Factor in the Circulating Blood.
Authors: David Azoulay, David Lavie, Moshe E. Gatt, Celia Surio, Luiza Akaria, Riki Perlman, Andrei Braester, Dina Ben Yehuda
Journal: Blood (2012)
AB0140 Altered Lipoproteins In Patients with Systemic Lupus Erythematosus Induce Augmented Oxidative Stress In Vitro and In Vivo
Authors: J.K. Park, J.Y. Moon, E.Y. Ahn, E.Y. Lee, E.B. Lee, K.H. Cho, Y.W. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing a cardiovascular disease which are not solely explained by the traditional cardiovascular (CV) risk factors. This higher CV risk might be associated with chemical and functional alteration of lipoproteins in SLE patients. <h3>Objectives</h3> This study aimed to investigate the lipoprotein modification from SLE patients and its effects on oxidative stress <i>in vivo</i> and <i>in vitro</i>. <h3>Methods</h3> A total of 35 SLE patients and 15 age and sex matched heathy controls (HC) were compared in regard to lipid profile including low density lipoprotein (LDL). Oxidation and susceptibility to oxidation as well as structure of LDL were measured by quantifying malondialdehyde (MDA), <i>de novo</i> formation of conjugated dienes in the presence of 5 uM CuSO4 and gel electrophoresis, respectively. The uptake of LDL by THP-1 cells was examined. In <i>vivo</i> radial oxygen species (ROS) formation and toxicity of LDL were examined in zebra fish embryos. <h3>Results</h3> LDL levels did not differ between SLE and HC (134.7±54.5 mg/dL vs. 118.3±29.9 mg/dL, P=0.277). LDL from SLE showed an increased fragmentation pattern during mobility through electrophoresis gel. As compared to HC-LDL, SLE-LDL were more oxidized (MDA level: 56.1±10 vs. 25.4±2.3 nM/mg, p&lt;0.001) and were also more susceptible to cupric-ion-mediated oxidation <i>in vitro</i> (3.5±0.5% vs. 1.9±1.9%, p&lt;0.001). In addition, more SLE-LDL were engulfed by THP-1 cells than HC-LDL (2501±401.2 AU vs. 524.1±59.8 AU, p&lt;0.001). Finally, the zebra fish embryos that were injected with SLE-LDL generated higher levels of ROS (1592±58.7 vs. 459.6±66.4, p&lt;0.001) and survived less (survival 49.1±2.8% vs. 87.8±1.2%, p&lt;0.001) as compared to those treated with HC-LDL. <h3>Conclusions</h3> LDL from SLE patients is altered with increased oxidation, structural instability and an augmented oxidative potential. Treatment with anti-oxidants might normalize the altered LDL property and so decrease the CV risk in SLE patients. <h3>Disclosure of Interest</h3> None declared
SP0148 Learning To Control – The Power over The Day-To-Day Setbacks Is … Ours!
Authors: M.F. Fonseca Santos
Journal: Annals of the Rheumatic Diseases (2016)

Mental training is a powerful tool to give back the control of the patient9s sensations, in pain relief and in emotional influence over the setbacks of the day. Being always complementary to medical treatment, mental training gives the patient the knowledge to manipulate the perceptions of pain and frustration, anger and sadness, contributing to reduce pain and to think differently about the difficulties in each patient9s life. Knowing how to deal with the day-to-day setbacks is very empowering, for the patient takes back the control of his feelings, well-being and self-awareness. There are several techniques that can be used in pain control – distraction, moving the pain from one spot to another, increasing and decreasing its perception, putting it in another platform (for example, out of our mind). These techniques can be chosen and adapted to each patient and to each pain in particular. Every time the patient uses mental training, he will also gain in relaxation, well-being and self-confidence, so important is this constant struggle. On the other hand, when the patient gains control of his thoughts, so many times depressive, frustrated, angry or desperate, he can then decide what to do, how to feel, how to act. The way we live and give power to suffering is a choice, not a burden. It has been already proved how our thoughts modify the body chemistry – now it9s time to do it regularly and get relief more quickly. The description of this suffering or rejection of the illness is also a good help and often shows exactly what it has been doing to the patient feelings. Writing about these sensations (of pain or frustration) and its part in day-to-day routine can show to each one how to deal with it and exactly how much damage are we prepared to let it do to our lives. Words written (where our eyes can read them, observing rather than feeling) will let our minds think about them and decide what to do next. Emotional writing, when used as a technique to relieve the patient from his suffering, is a wonderful tool. Doing this in a group session can be the beginning of a different way of feeling. Most people live alone with their suffering. Hearing what others say and write about this, and how each one copes with their illness, can make this loneliness disappear, giving space to a new way to live beyond this illness. <h3>Disclosure of Interest</h3> None declared
Home Telemetric System for Pulmonary Function Surveillance: A Useful Procedure for Detection of Late-Onset Noninfectious Pulmonary Complications (LONIPC) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Amélie Guihot, Marie-Hélène Becquemin, Louis-Jean Couderc, Odile Randrianarivelo, Elisabeth Rivaud, Bruno Philippe, Hélène Neveu, Jean-Paul Vernant, Nathalie Dhedin
Journal: Blood (2005)
Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,
Authors: Kevin Tay, Gillianne Lai, Elaine J Chua, Whee Sze Ong, Tiffany Tang, Richard Quek, Daryl Tan, Leonard Tan, Miriam Tao, Soo Yong Tan, Soon Thye Lim
Journal: Blood (2011)
Expression of DNMT Isoforms Is Differentially Associated with Aberrant Promotor Methylation in MDS Hematopoietic Progenitor Cells during Lineage Specific Differentiation.
Authors: Olaf J. Hopfer, Martina Komor, Ina S. Koehler, Matthias Schulze, Claudia Freitag, Dieter Hoelzer, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2006)
Aberrant gene expression with deficient apoptotic keratinocyte clearance may predispose to polymorphic light eruption
Authors: S. Lembo, J.L.M. Hawk, G.M. Murphy, K. Kaneko, A.R. Young, J.M. McGregor, S.L. Walker, R.A. Palmer
Journal: British Journal of Dermatology (2016)

Polymorphic light eruption (PLE) is the commonest photodermatosis, demonstrating intermittently appearing non-scarring pruritic, erythematous papules, vesicles or plaques on patient skin within hours of ultraviolet radiation (UVR) exposure. It depends on genetic susceptibility as well as environmental UVR exposure and is apparently a failure of normal UVR-induced immunosuppression in the presence of simultaneously produced skin photoneoantigens1,2, with a resulting increased immune response. Reduced TNF-α, IL-4 and IL-10 expression, a lack of neutrophils, reduced T-helper-1/T-helper-2 skewing and reduced Langerhans cell migration have also been demonstrated in UVB-irradiated PLE skin3. Bead-array immunoassay studies have further revealed significantly higher PLE baseline IL-1β and CCL11 (eotaxin) spring plasma levels4, while decreased TGFs1, IL-10 and receptor activator of nuclear factor kappa-B ligand (RANKL) epidermal and dermal expression, and reduced T-reg cells occur in UVA-1-irradiated patients5, as well as decreased T-reg cell function in all PLE patients, irradiated or not6.

This article is protected by copyright. All rights reserved.
AB0583 Long-Term Integrated Treatment with Bosentan and Iloprost Increases, Independently from Other Clinical Characteristics, The Absolute Number of Capillaries in Systemic Sclerosis Patients: A Nailfold Capillaroscopic Analysis
Authors: A.C. Trombetta, A. Sulli, C. Pizzorni, S. Paolino, E. Alessandri, V. Smith, B. Ruaro, M. Cutolo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Iloprost (ILO) and bosentan (BOSE) integrated therapy was demonstrated to improve microvascular structure in systemic sclerosis (SSc) patients, in two long-term follow up studies [1]. <h3>Objectives</h3> Since the alterations in capillary number seem to predict the incidence of clinical SSc complications [2], present study aimed to quantify, by nailfold videocapillaroscopy (NVC), long-term effects of BOSE treatment on nailfold capillary absolute number and their possible correlation with clinical parameters of the disease. <h3>Methods</h3> Thirty SSc patients entered the study, with a follow up of for 4 years. Fifteen patients were treated with ILO mono-therapy (80 μg/day, for 5 continuous days, every 3 months), while other 15 patients, because of the onset of systolic pulmonary hypertension (sPAP) or digital ulcers (DUs) were treated with BOSE (125 mg twice/day) and ILO integrated therapy (ILO+BOSE). Nailfold capillaries absolute number, DU incidence, diffusing capacity of the lung for carbon monoxide (DLCO), sPAP and renal artery resistive index (RI) were evaluated yearly. Friedman test, Cochran9s q test, Marginal homogeneity and mixed modelling were used to study variables with repeated measures. A p value lower then 0.05 was considered significant. <h3>Results</h3> In the ILO+BOSE group, capillary absolute number was found to have a significant increase (p=0.01) from T0: 6.8±1.3 to T4: 7.8±1.5 (14.7%), whereas in the ILO group, a non-significant decrease in capillary number from T0: 7.18±0.5 to T4: 6.5±1.1 (9.4%) was found. According to multivariate analysis, the most significant associations, other then BOSE treatment, were observed between capillary number increase and baseline capillaroscopic "Early" pattern (p&lt;0.0001), lcSSc subtype (p=0.001), while it was independent from other clinical characteristics. In the ILO+BOSE group there was a significant reduction in the annual incidence of new DUs from T0 (10/15 patients) to T4 (2/15 patients) (80%; p=0.0042) and no further negative significant changes were observed in DLCO and sPAP. On the contrary, in the ILO group, DLCO was significantly reduced (8.1%, p=0.039) and sPAP increased (15%, p=0.04) during the follow up. RI did not change significantly in both groups. <h3>Conclusions</h3> Capillary absolute number count seems a reliable parameter to evaluate long-term effects of BOSE on microvasculature in SSc. A significant reduction in the annual incidence of new DUs and stabilization of lung function was observed and appeared to be associated to the increased number of capillaries during a four-years integrated treatment with BOSE and ILO. <h3>References</h3> Cutolo M et al. 2013;40:40–5. Smith V et al. 2011;70:180–3. <h3>Disclosure of Interest</h3> None declared
The Hospital at Home Program for Older Adults
Authors: Bruce Leff, Tacara Soones, Linda DeCherrie
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Evaluation of Human Polyomavirus (BKV)–Specific T Cell Immune Reconstitution in Allogeneic Haematopoietic Stem Cell Transplant Recipients,
Authors: Francesca Lorraine Wei Inng Lim, Ai Ling Teo, Yvonne SM Loh, William YK Hwang, Yeow-Tee Goh, Khoon Lin Ling, Yeh Ching Linn
Journal: Blood (2011)
Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.
Authors: Farrukh Awan, Neil E. Kay, Melanie Davis, Wenting Wu, Nelson Leung, Diane F. Jelinek, Renee Tschumper, Charla Secreto, Thomas S. Lin, Michael R Grever, Tait Shanafelt, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, Gerard Lozanski, John C. Byrd, David Lucas
Journal: Blood (2008)
Airway eosinophil migration into lymph nodes in mice depends on leukotriene C<sub>4</sub>
Authors: H.‐B. Wang, P. Akuthota, Y. Kanaoka, P. F. Weller
Journal: Allergy (2016)

We previously demonstrated in mice that airway eosinophils traffic from the airway lumen into lung-draining paratracheal lymph nodes. However, mechanisms whereby eosinophils traverse from the lungs and home to paratracheal lymph nodes remain unclear. We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficking from lungs to paratracheal lymph nodes.The expression of CCR7 was determined by flow cytometry. Transwell assays were used to test chemotactic responses of leukotriene C4 synthase-deficient and control airway eosinophils to the chemokine CCL19 ex vivo. Eosinophils from the spleens of IL-5 transgenic mice, fluorescently labeled ex vivo, were intratracheally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged leukotriene C4 synthase-deficient and control mice. Eosinophils were identified by microscopy and flow cytometry in the lungs and paratracheal lymph nodes.Mouse eosinophils expressed CCR7, the receptor for CCL19, and responded chemotactically to CCL19. Leukotriene C4 synthase-deficient eosinophils exhibited impaired chemotaxis to CCL19 that was restored by exogenous leukotriene C4 . The migration of intratracheally injected eosinophils into paratracheal lymph nodes from distal alveolar lung was diminished in leukotriene C4 synthase-deficient mice compared with wild-type mice, with increased retention of eosinophils in the lungs of leukotriene C4 synthase-deficient mice. Exogenous administration of leukotriene C4 restored trafficking of eosinophils to paratracheal lymph nodes in leukotriene C4 synthase-deficient mice.Our findings that cysteinyl leukotrienes are involved in regulating airway and lung eosinophil migration into paratracheal lymph nodes identify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary trafficking of eosinophils in experimental allergic asthma.
Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.
Authors: Annemiek Broyl, Dirk Hose, Yvonne de Knegt, Henk Lokhorst, Hartmut Goldschmidt, Mark van Duin, Pieter Sonneveld
Journal: Blood (2007)
Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403
Authors: Lawrence D. Kaplan, Sin-Ho Jung, Wendy Stock, Nancy L. Bartlett, Brandelyn Pitcher, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, Noreen Fulton, Eric D. Hsi, David D Hurd, Myron Czuczman, John P. Leonard, Bruce D. Cheson
Journal: Blood (2015)
Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.
Authors: Lapo Alinari, Fengting Yan, Porsha Smith, John T. Patton, Carl Quinion, Bo Yu, Christian Tyler Earl, Mark E Lustberg, Lynda Villagomez, Erin K Hertlein, John C. Byrd, Leona Ayers, Tasneem Motiwala, Sarmila Majumder, Chenglong Li, Said Sif, Samson T. Jacob, Robert A. Baiocchi
Journal: Blood (2012)
Wharton's jelly-derived mesenchymal stem cell therapy to improve β-cell function in patients with type 1 diabetes and ketoacidosis: a single-centre, single-group, open-label, phase 2 trial
Authors: Lirong Li, Jing Lu, Shanmei Shen, Xiaolei Jia, Dalong Zhu
Journal: The Lancet Diabetes & Endocrinology (2016)